Clinical trial
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
NCT00421213 · Alaunos Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00421213 |
|---|---|
| Title | Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers |
| Official title | Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers |
| Lead sponsor | Alaunos Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hematologic Neoplasms, Bone Marrow Neoplasms, Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Darinaparsin |
| Enrollment | 50 |
| Start date | Dec 1, 2006 |
| Primary completion | Apr 1, 2012 |
| Completion | Apr 1, 2012 |
| First posted | Jan 11, 2007 |
| Last update posted | Jul 19, 2012 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: